Iteos Therapeutics Stock Analysis
| ITOS Stock | USD 6.97 0.09 1.31% |
Iteos Therapeutics is overvalued with Real Value of 6.04 and Target Price of 25.0. The main objective of Iteos Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Iteos Therapeutics is worth, separate from its market price. There are two main types of Iteos Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Iteos Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Iteos Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Iteos Stock trading window is adjusted to America/New York timezone.
Iteos |
Iteos Stock Analysis Notes
About 91.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.32. The entity had not issued any dividends in recent years. Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Iteos Therapeutics call Michel Detheux at 339 217 0161 or check out https://www.iteostherapeutics.com.Iteos Therapeutics Investment Alerts
| Iteos Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (134.41 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (98.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Wall Street Analysts Think iTeos Therapeutics Could Surge 212.5 percent Read This Before Placing a Bet |
Iteos Therapeutics Upcoming and Recent Events
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Iteos Largest EPS Surprises
Earnings surprises can significantly impact Iteos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | 0.1 | 0.03 | -0.07 | 70 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.39 | 0.09 | 18 | ||
2020-11-12 | 2020-09-30 | -0.36 | -0.48 | -0.12 | 33 |
Iteos Therapeutics Environmental, Social, and Governance (ESG) Scores
Iteos Therapeutics' ESG score is a quantitative measure that evaluates Iteos Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Iteos Therapeutics' operations that may have significant financial implications and affect Iteos Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Iteos Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 922.1 K | 683 Capital Management Llc | 2024-12-31 | 918.1 K | Vestal Point Capital Lp | 2024-12-31 | 900 K | Citigroup Inc | 2024-12-31 | 853.8 K | Renaissance Technologies Corp | 2024-12-31 | 837.2 K | Goldman Sachs Group Inc | 2024-12-31 | 730.5 K | Geode Capital Management, Llc | 2024-12-31 | 644.9 K | State Street Corp | 2024-12-31 | 585.9 K | Caption Management, Llc | 2024-12-31 | 509.8 K | Blackrock Inc | 2024-12-31 | 3.8 M | Boxer Capital Llc | 2024-09-30 | 2.9 M |
Iteos Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 262.78 M.Iteos Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.23) | (0.24) |
Management Efficiency
Iteos Therapeutics has return on total asset (ROA) of (0.1447) % which means that it has lost $0.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2307) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.26 in 2025. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 186.3 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 4.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.58 | 8.77 | |
| Tangible Book Value Per Share | 14.58 | 8.77 | |
| Enterprise Value Over EBITDA | (1.14) | (1.19) | |
| Price Book Value Ratio | 0.53 | 0.50 | |
| Enterprise Value Multiple | (1.14) | (1.19) | |
| Price Fair Value | 0.53 | 0.50 | |
| Enterprise Value | 199.9 M | 189.9 M |
The management team at Iteos Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Technical Drivers
As of the 24th of March, Iteos Therapeutics retains the Risk Adjusted Performance of (0.04), standard deviation of 2.51, and Market Risk Adjusted Performance of (0.15). Iteos Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Iteos Therapeutics mean deviation and maximum drawdown to decide if Iteos Therapeutics is priced fairly, providing market reflects its last-minute price of 6.97 per share. Given that Iteos Therapeutics has information ratio of (0.03), we strongly advise you to confirm Iteos Therapeutics's regular market performance to make sure the company can sustain itself at a future point.Iteos Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Iteos Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Iteos Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Iteos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iteos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iteos Therapeutics Outstanding Bonds
Iteos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iteos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iteos bonds can be classified according to their maturity, which is the date when Iteos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ITC HLDGS P Corp BondUS465685AH81 | View | |
| ITC HLDGS P Corp BondUS465685AK11 | View | |
| US465685AQ80 Corp BondUS465685AQ80 | View | |
| ITC HLDGS P Corp BondUS465685AP08 | View | |
| ITC 495 22 SEP 27 Corp BondUS465685AR63 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Iteos Therapeutics Predictive Daily Indicators
Iteos Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Iteos Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Iteos Therapeutics Corporate Filings
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 5th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 21st of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Iteos Therapeutics Forecast Models
Iteos Therapeutics' time-series forecasting models are one of many Iteos Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Iteos Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Iteos Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Iteos Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Iteos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Iteos Therapeutics. By using and applying Iteos Stock analysis, traders can create a robust methodology for identifying Iteos entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (3.44) | (3.61) | |
| Operating Profit Margin | (4.56) | (4.79) | |
| Net Loss | (3.84) | (4.03) | |
| Gross Profit Margin | 0.93 | 1.07 |
Current Iteos Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Iteos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Iteos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 25.0 | Strong Buy | 6 | Odds |
Most Iteos analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Iteos stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Iteos Therapeutics, talking to its executives and customers, or listening to Iteos conference calls.
Iteos Stock Analysis Indicators
Iteos Therapeutics stock analysis indicators help investors evaluate how Iteos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Iteos Therapeutics shares will generate the highest return on investment. By understating and applying Iteos Therapeutics stock analysis, traders can identify Iteos Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 251.5 M | |
| Common Stock Shares Outstanding | 40.5 M | |
| Total Stockholder Equity | 590.3 M | |
| Tax Provision | 14.1 M | |
| Quarterly Earnings Growth Y O Y | -0.886 | |
| Property Plant And Equipment Net | 10 M | |
| Cash And Short Term Investments | 494.6 M | |
| Cash | 142.1 M | |
| Accounts Payable | 8.5 M | |
| Net Debt | -137 M | |
| 50 Day M A | 7.3931 | |
| Total Current Liabilities | 40.4 M | |
| Other Operating Expenses | 194.5 M | |
| Non Current Assets Total | 177.4 M | |
| Forward Price Earnings | 12.5628 | |
| Non Currrent Assets Other | 7.1 M | |
| Stock Based Compensation | 29.9 M |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.